New hope for aHUS: could a simple pill replace infusions?

NCT ID NCT05935215

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times

Summary

This study looks at whether adults with aHUS (a rare blood disorder) can safely switch from their current infusion treatment to a daily pill called iptacopan. About 50 participants will take iptacopan for 12 months to see if it prevents dangerous blood clots. The goal is to find a more convenient treatment option that still controls the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Novartis Investigative Site
WITHDRAWN

Nanjing, Jiangsu, 210009, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100034, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100730, China
Novartis Investigative Site
WITHDRAWN

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Paris, 75015, France
Novartis Investigative Site
RECRUITING

Paris, 75970, France
Novartis Investigative Site
RECRUITING

Rouen, 76031, France
Novartis Investigative Site
RECRUITING

Toulouse, 31054, France
Novartis Investigative Site
RECRUITING

Tours, 37044, France
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Kiel, 24105, Germany
Novartis Investigative Site
RECRUITING

Ranica, BG, 24020, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20122, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00168, Italy
Novartis Investigative Site
RECRUITING

Matsumoto-shi, Nagano, 3908510, Japan
Novartis Investigative Site
RECRUITING

Iruma-gun, Saitama, 3500495, Japan
Novartis Investigative Site
RECRUITING

Bunkyo Ku, Tokyo, 113-8655, Japan
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Córdoba, 14004, Spain
Novartis Investigative Site
RECRUITING

Málaga, 29010, Spain
Novartis Investigative Site
RECRUITING

Seville, 41013, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
WITHDRAWN

Izmir, Balcova, 35340, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Köseköy, Kocaeli, 41380, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Mersin, Yenisehir, 33110, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Glasgow, Scotland, G51 4TF, United Kingdom
Novartis Investigative Site
RECRUITING

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
Novartis Investigative Site
RECRUITING

London, NW1 2BU, United Kingdom

Conditions

Explore the condition pages connected to this study.

ATYPICAL HEMOLYTIC UREMIC SYNDROME